Home > Insider Trading > Filing (0001179110-19-001436)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1650664	Editas Medicine Inc.	EDIT	Biological Products, (No Disgnostic Substances) (2836)	464097528

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1657434	F. A. Andrew Hack	C/O Editas Medicine, Inc. 11 Hurley St. Cambridge MA 02141	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-04	6,895	$6.48	6,895	No	4	M	Direct
Common Stock	Disposition	2019-02-04	6,895	$21.39	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2019-02-04	6,895	$0.00	6,895	$6.48

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,618		2025-09-13	No	4	M	Direct

Footnotes

The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 28, 2018.
This transaction was executed in multiple trades at prices ranging from $21.16 to $21.805. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.